DNLI Q1 2019 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+556.0% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$43M-1010.9% margin

Net Income

-$39M-927.3% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

-96.7%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$32M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$677M

Total Liabilities

$160M

Stockholders' Equity

$517M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$641,000	+556.0%
Gross Profit	$4M	$641,000	+556.0%
Operating Income	-$43M	-$26M	-65.1%
Net Income	-$39M	-$24M	-64.7%

Revenue Segments

Alzheimer's Disease Services

$4M100%